公开(公告)号：US20090247459A1

公开(公告)日：2009-10-01

申请号：US12267491

申请日：2008-11-07

申请人： Hans-Peter Schwarz ,  Peter Turecek

发明人： Hans-Peter Schwarz ,  Peter Turecek

IPC分类号： A61K38/36 ,  A61K38/37 ,  A61P7/00 ,  C08G65/00

CPC分类号： A61K38/37 ,  A61K47/60 ,  A61K47/61 ,  C07K14/755 ,  C08G65/329 ,  C08H1/00 ,  C08L63/00 ,  C08L2203/02

摘要： The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.

摘要翻译： 本发明提供了通过抑制与间隙受体的相互作用来增加凝血蛋白的存活的新方法。 本发明还提供了制备抑制凝血蛋白清除受体的组合物的方法。 共轭凝血蛋白，包括其组合物和制剂，也由本发明提供。

公开(公告)号：US6013620A

公开(公告)日：2000-01-11

申请号：US926845

申请日：1997-09-11

申请人： Peter Turecek ,  Hans-Peter Schwarz ,  Gerda Redl

发明人： Peter Turecek ,  Hans-Peter Schwarz ,  Gerda Redl

IPC分类号： A61K38/04 ,  A61K38/43 ,  A61K38/46 ,  A61K38/48 ,  A61P7/02 ,  C12N9/64 ,  A61K35/14 ,  A61K38/16 ,  C07K14/745

CPC分类号： C12N9/6437 ,  A61K38/4846 ,  C12N9/647 ,  C12Y304/21021 ,  Y10S514/834

摘要： The invention relates to a pharmaceutical composition for the treatment of patients with blood coagulation diseases which are caused by coagulation factor deficiency and/or inhibitors of coagulation factors, whereby the composition as a FEIB-activity and is characterized in that it has Factor VIIa and at least one further active ingredient and the activity of at least 10 Factor VIIa units per unit FEIBA. Additionally, the invention comprises a method for the production of the pharmaceutical preparation and its use.

摘要翻译： 本发明涉及一种用于治疗由凝血因子缺乏引起的凝血疾病患者和/或凝血因子抑制剂的药物组合物，其中组合物作为FEIB活性，其特征在于其具有因子VIIa和 至少一种其他活性成分和至少10个因子VIIa单位每单位FEIBA的活性。 此外，本发明包括制备药物制剂及其用途的方法。

公开(公告)号：US5866122A

公开(公告)日：1999-02-02

申请号：US821763

申请日：1997-03-20

申请人： Peter Turecek ,  Hans-Peter Schwarz ,  Johann Eibl

发明人： Peter Turecek ,  Hans-Peter Schwarz ,  Johann Eibl

IPC分类号： G01N33/86 ,  A61K31/435 ,  A61K31/60 ,  A61K38/00 ,  A61K38/36 ,  A61K38/43 ,  A61K38/48 ,  A61K38/55 ,  A61K38/57 ,  A61K45/00 ,  A61K47/48 ,  A61P3/14 ,  A61P7/02 ,  A61P7/04 ,  A61P39/02 ,  C07K1/18 ,  C07K1/20 ,  C07K1/36 ,  C07K14/745 ,  C12N9/64 ,  C12N9/74

CPC分类号： C12N9/6432 ,  A61K38/4833 ,  A61K38/4846 ,  A61K38/57 ,  C07K1/18 ,  C07K1/20 ,  C07K1/36 ,  C07K14/745 ,  C12N9/6429 ,  C12N9/647 ,  C12Y304/21005 ,  C12Y304/21006 ,  Y10S514/822

摘要： There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

公开(公告)号：US08828676B2

公开(公告)日：2014-09-09

申请号：US13281519

申请日：2011-10-26

申请人： Alfred Weber ,  Peter Turecek ,  Hans-Peter Schwarz

发明人： Alfred Weber ,  Peter Turecek ,  Hans-Peter Schwarz

IPC分类号： C12Q1/56 ,  G01N31/00 ,  G01N33/68

CPC分类号： G01N33/6842 ,  G01N2333/4724 ,  G01N2333/755 ,  Y10S436/827 ,  Y10T436/10 ,  Y10T436/105831 ,  Y10T436/106664

摘要： The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.

摘要翻译： 本发明一般涉及当血浆蛋白质和重组蛋白质基本上相同的蛋白质时，基于蛋白质糖基化的差异，在样品中检测和定量血浆衍生的蛋白质和重组蛋白质的方法。

公开(公告)号：US08343748B2

公开(公告)日：2013-01-01

申请号：US12124390

申请日：2008-05-21

申请人： Peter Matthiessen ,  Stefan Romeder-Finger ,  Peter Turecek ,  Hans-Peter Schwarz

发明人： Peter Matthiessen ,  Stefan Romeder-Finger ,  Peter Turecek ,  Hans-Peter Schwarz

IPC分类号： C12N9/14 ,  C07K1/18 ,  C07K1/20

CPC分类号： C12N9/6454 ,  B01D15/363 ,  C12Y304/21075

摘要： Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on CAPTO MMC™ (mixed cation exchange/hydrophobic interaction gel) resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after CAPTO MMC™ (mixed cation exchange/hydrophobic interaction gel) chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%.

摘要翻译： 重组截短的人弗林蛋白酶在CHO细胞中表达，并通过超滤和渗滤浓缩约50倍。 浓缩物通过CAPTO MMC TM（混合阳离子交换/疏水相互作用凝胶）上的柱色谱纯化，得到30-50倍纯化因子，产率至少为60％。 在CAPTO MMC TM（混合阳离子交换/疏水相互作用凝胶）色谱之后获得的至少20％的纯制剂已经具有允许亲VWF的柱上成熟的纯化度。 然后进行额外的精氨酸琼脂糖层析纯化。 用于纯化截短的人弗林蛋白酶的这种两柱方法产生几乎纯的弗林蛋白酶制剂，其具有约290,000U弗林蛋白/ mg蛋白质的比活性，约50％的产率。

公开(公告)号：US20110206554A1

公开(公告)日：2011-08-25

申请号：US13100570

申请日：2011-05-04

申请人： Heinz Anderle ,  Peter Matthiessen ,  Hans-Peter Schwarz ,  Peter Turecek ,  Thomas Kreil ,  Daniel R. Boggs

发明人： Heinz Anderle ,  Peter Matthiessen ,  Hans-Peter Schwarz ,  Peter Turecek ,  Thomas Kreil ,  Daniel R. Boggs

IPC分类号： A61L2/10 ,  A61L2/08 ,  B01J19/08 ,  A61L2/24

CPC分类号： A61L2/10 ,  A23L3/26 ,  A23L3/28 ,  A61L2/0011 ,  A61L2/28 ,  G01N21/33 ,  H05B3/0052

摘要： The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.

摘要翻译： 本发明涉及一种用于确定来自一种或多种光源的有效剂量的单色或多色光以灭活存在于生物流体中，优选非透明流体中的微生物的方法。 此外，提供了在流通反应器中的生物流体中的微生物灭活的方法。 此外，本发明有利地提供具有一个或多个恒温光源的流通反应器。 本发明还提供一种控制从一个或多个光源发射的单色或多色光的光总量的方法，以有效地灭活间歇反应器中存在于生物流体中的微生物。

公开(公告)号：US20100126866A1

公开(公告)日：2010-05-27

申请号：US12621051

申请日：2009-11-18

申请人： Jasmin Kemptner ,  Martina Marchetti-Deschmann ,  Juergen Siekmann ,  Peter Turecek ,  Hans-Peter Schwarz ,  Guenter Allmaier

发明人： Jasmin Kemptner ,  Martina Marchetti-Deschmann ,  Juergen Siekmann ,  Peter Turecek ,  Hans-Peter Schwarz ,  Guenter Allmaier

IPC分类号： B01D59/42

CPC分类号： G01N27/624

摘要： Disclosed herein are methods of determining polydispersity (PDI) and molecular mass distribution (MMD) of reactive PEG samples using mass spectrometry. More specifically, a mass spectrometry method called GEMMA is used to determine PDI and MMD of PEG samples which provides more accurate measurements for high molecular weight PEG samples than prior known MALDI-TOF analysis.

摘要翻译： 本文公开了使用质谱测定反应性PEG样品的多分散性（PDI）和分子量分布（MMD）的方法。 更具体地，使用称为GEMMA的质谱法来测定PEG样品的PDI和MMD，其提供了比现有已知的MALDI-TOF分析更高精度的高分子量PEG样品的测量。

公开(公告)号：US20100115637A1

公开(公告)日：2010-05-06

申请号：US12606884

申请日：2009-10-27

申请人： Hans-Peter Schwarz ,  Eva-Maria Muchitsch ,  Peter Turecek

发明人： Hans-Peter Schwarz ,  Eva-Maria Muchitsch ,  Peter Turecek

IPC分类号： G01N33/00 ,  A01K67/00

CPC分类号： A61K49/0008 ,  A01K67/027 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2217/052 ,  A01K2217/054 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0306 ,  A01K2267/0325 ,  A01K2267/0381 ,  C12N15/8509

摘要： The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.

摘要翻译： 本发明涉及用于测试治疗凝血障碍的各种药剂的动物模型的开发。 更具体地，本发明涉及在各种小鼠品系中使用超大分子量多聚体维生素B因子（VWF）以诱导血小板减少性紫癜（TTP）样症状，用于开发TTP小鼠模型。 本发明还提供了产生用于鉴定有效治疗TTP的生物活性化合物的动物疾病模型和筛选方法。

公开(公告)号：US20060045796A1

公开(公告)日：2006-03-02

申请号：US10924579

申请日：2004-08-24

申请人： Heinz Anderle ,  Peter Matthiessen ,  Hans-Peter Schwarz ,  Peter Turecek ,  Thomas Kreil ,  Daniel Boggs

发明人： Heinz Anderle ,  Peter Matthiessen ,  Hans-Peter Schwarz ,  Peter Turecek ,  Thomas Kreil ,  Daniel Boggs

IPC分类号： A61L2/08 ,  A61L2/10

CPC分类号： A61L2/10 ,  A23L3/26 ,  A23L3/28 ,  A61L2/0011 ,  A61L2/28 ,  G01N21/33 ,  H05B3/0052

摘要： The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.

公开(公告)号：US20060003921A1

公开(公告)日：2006-01-05

申请号：US11218406

申请日：2005-09-02

申请人： Hans-Peter Schwarz ,  Katalin Varadi ,  Peter Turecek ,  Hendrik Hemker ,  Suzette Beguin

发明人： Hans-Peter Schwarz ,  Katalin Varadi ,  Peter Turecek ,  Hendrik Hemker ,  Suzette Beguin

IPC分类号： A61K38/37

CPC分类号： A61K38/37

摘要： Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation.

摘要翻译： 描述了一种用于治疗凝血障碍的药物制剂，其包含有效量的vWF前肽以及制备这种制剂的方法。